Integra LifeSciences (NASDAQ:IART) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Misses Expectations
Integra LifeSciences (NASDAQ:IART) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Misses Expectations TradingView
Covered in this story
What has happened since
- Integra Lifesciences Holdings Corp is up 4.1% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Integra Lifesciences Holdings Corp
- Wells Fargo: $12.7 → $15 by Oct 2027 · Equal Weight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $IART yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Integra Lifesciences Holdings Corp →Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.